Health Care


Health Care

View on TED@BCG

Health Care in Emerging Markets

May 2016
Emerging economies can avoid the traps that have ensnared developed countries and instead build health systems that are well suited to the reality on the ground.

Decision-Making in R&D

April 2016
Reorganization is a powerful lever for boosting company performance, but the results are often disappointing. A smart new approach dramatically increases the likelihood of success.
January 2016
Despite general challenges to productivity in biopharma R&D, a few companies continue to excel. The key is their superior organizational effectiveness, which enhances cooperative behavior among R&D staff.
February 2015
R&D productivity has been declining for decades, but a record 53 new therapeutic drugs approved by the U.S. FDA in 2014 suggest that the biopharma industry's fortunes have changed.
December 2013
BCG research published in Nature Reviews Drug Discovery does not show a correlation between company size and the likelihood of R&D success. But if size does not matter, what does?

Focus on Biopharma

April 2016
Top-line growth is an imperative for medtech and biopharma. With so much pressure to contain costs, these companies need to find new ways to thrive and grow.

Value-Based Health Care

December 2015
A new European Parliament directive aims for a procurement approach that considers patient outcomes and total costs over the life of health care purchases.

The Payer Agenda

April 2016
As large US health plans consolidate and grow bigger and more powerful, Blue Cross and Blue Shield plans need to take steps to become more competitive.
April 2016
As the health insurance market continues to defy expectations, payers must set aside failed predictions and address what's really happening in their markets.
September 2015
By facilitating better decision making, payers can lower costs by €100 million to €200 million for every million lives covered and at the same time improve patient outcomes.
July 2015
Consolidation won’t move the needle on health care value unless the newly combined insurers use some of the savings to invest in and extend their clinical capabilities.